279 related articles for article (PubMed ID: 9808567)
21. CpG-containing oligodeoxynucleotides, in combination with conventional adjuvants, enhance the magnitude and change the bias of the immune responses to a herpesvirus glycoprotein.
Ioannou XP; Gomis SM; Karvonen B; Hecker R; Babiuk LA; van Drunen Littel-van den Hurk S
Vaccine; 2002 Nov; 21(1-2):127-37. PubMed ID: 12443671
[TBL] [Abstract][Full Text] [Related]
22. CpG ODN 2006 and IL-12 are comparable for priming Th1 lymphocyte and IgG responses in cattle immunized with a rickettsial outer membrane protein in alum.
Zhang Y; Palmer GH; Abbott JR; Howard CJ; Hope JC; Brown WC
Vaccine; 2003 Jul; 21(23):3307-18. PubMed ID: 12804862
[TBL] [Abstract][Full Text] [Related]
23. Idiotype/granulocyte-macrophage colony-stimulating factor fusion protein as a vaccine for B-cell lymphoma.
Tao MH; Levy R
Nature; 1993 Apr; 362(6422):755-8. PubMed ID: 8469286
[TBL] [Abstract][Full Text] [Related]
24. Enhanced immune response to T-independent antigen by using CpG oligodeoxynucleotides encapsulated in liposomes.
Li WM; Bally MB; Schutze-Redelmeier MP
Vaccine; 2001 Oct; 20(1-2):148-57. PubMed ID: 11567759
[TBL] [Abstract][Full Text] [Related]
25. Immunostimulatory CpG-oligodeoxynucleotides induce a factor that inhibits macrophage adhesion.
Macfarlane DE; Manzel L
J Lab Clin Med; 1999 Nov; 134(5):501-9. PubMed ID: 10560944
[TBL] [Abstract][Full Text] [Related]
26. Dendritic cells (DC) activated by CpG DNA ex vivo are potent inducers of host resistance to an intracellular pathogen that is independent of IL-12 derived from the immunizing DC.
Ramírez-Pineda JR; Fröhlich A; Berberich C; Moll H
J Immunol; 2004 May; 172(10):6281-9. PubMed ID: 15128817
[TBL] [Abstract][Full Text] [Related]
27. Transfection of immature murine bone marrow-derived dendritic cells with the granulocyte-macrophage colony-stimulating factor gene potently enhances their in vivo antigen-presenting capacity.
Curiel-Lewandrowski C; Mahnke K; Labeur M; Roters B; Schmidt W; Granstein RD; Luger TA; Schwarz T; Grabbe S
J Immunol; 1999 Jul; 163(1):174-83. PubMed ID: 10384114
[TBL] [Abstract][Full Text] [Related]
28. CpG-DNA stimulates cellular and humoral immunity and promotes Th1 differentiation in aged BALB/c mice.
Maletto B; Rópolo A; Morón V; Pistoresi-Palencia MC
J Leukoc Biol; 2002 Sep; 72(3):447-54. PubMed ID: 12223511
[TBL] [Abstract][Full Text] [Related]
29. Oligodeoxynucleotides containing CpG motifs induce low levels of TNF-alpha in human B lymphocytes: possible adjuvants for Th1 responses.
Bohle B; Orel L; Kraft D; Ebner C
J Immunol; 2001 Mar; 166(6):3743-8. PubMed ID: 11238615
[TBL] [Abstract][Full Text] [Related]
30. [Impact of different adjuvants on immunogenicity of the HBV particle vaccine containing the S + preS1 fusion antigen in Balb/C mice].
Chen H; Deng Y; Tan W; Wang W; Yin X; Guan J; Wang W; Ruan L
Sheng Wu Gong Cheng Xue Bao; 2010 Jan; 26(1):74-8. PubMed ID: 20353095
[TBL] [Abstract][Full Text] [Related]
31. Induction of multispecific Th-1 type immune response against HCV in mice by protein immunization using CpG and Montanide ISA 720 as adjuvants.
Qiu Q; Wang RY; Jiao X; Jin B; Sugauchi F; Grandinetti T; Alter HJ; Shih JW
Vaccine; 2008 Oct; 26(43):5527-5534. PubMed ID: 18675871
[TBL] [Abstract][Full Text] [Related]
32. CpG DNA functions as an effective adjuvant for the induction of immune responses in aged mice.
Manning BM; Enioutina EY; Visic DM; Knudson AD; Daynes RA
Exp Gerontol; 2001 Dec; 37(1):107-26. PubMed ID: 11738152
[TBL] [Abstract][Full Text] [Related]
33. CpG oligonucleotides enhance the tumor antigen-specific immune response of an anti-idiotype antibody-based vaccine strategy in CEA transgenic mice.
Saha A; Baral RN; Chatterjee SK; Mohanty K; Pal S; Foon KA; Primus FJ; Krieg AM; Weiner GJ; Bhattacharya-Chatterjee M
Cancer Immunol Immunother; 2006 May; 55(5):515-27. PubMed ID: 16044253
[TBL] [Abstract][Full Text] [Related]
34. Attachment of class B CpG ODN onto DOTAP/DC-chol liposome in nasal vaccine formulations augments antigen-specific immune responses in mice.
Tada R; Muto S; Iwata T; Hidaka A; Kiyono H; Kunisawa J; Aramaki Y
BMC Res Notes; 2017 Jan; 10(1):68. PubMed ID: 28126014
[TBL] [Abstract][Full Text] [Related]
35. CpG oligodeoxynucleotides act as adjuvants that switch on T helper 1 (Th1) immunity.
Chu RS; Targoni OS; Krieg AM; Lehmann PV; Harding CV
J Exp Med; 1997 Nov; 186(10):1623-31. PubMed ID: 9362523
[TBL] [Abstract][Full Text] [Related]
36. Co-administration of polyphosphazenes with CpG oligodeoxynucleotides strongly enhances immune responses in mice immunized with Hepatitis B virus surface antigen.
Mutwiri G; Benjamin P; Soita H; Babiuk LA
Vaccine; 2008 May; 26(22):2680-8. PubMed ID: 18430493
[TBL] [Abstract][Full Text] [Related]
37. CpG oligodeoxynucleotide-based therapy of lymphoid malignancies.
Weiner GJ
Adv Drug Deliv Rev; 2009 Mar; 61(3):263-7. PubMed ID: 19168102
[TBL] [Abstract][Full Text] [Related]
38. Granulocyte/macrophage-colony stimulating factor produced by recombinant avian poxviruses enriches the regional lymph nodes with antigen-presenting cells and acts as an immunoadjuvant.
Kass E; Panicali DL; Mazzara G; Schlom J; Greiner JW
Cancer Res; 2001 Jan; 61(1):206-14. PubMed ID: 11196163
[TBL] [Abstract][Full Text] [Related]
39. The immunobiology and clinical potential of immunostimulatory CpG oligodeoxynucleotides.
Weiner GJ
J Leukoc Biol; 2000 Oct; 68(4):455-63. PubMed ID: 11037965
[TBL] [Abstract][Full Text] [Related]
40. Vaccination with Leishmania soluble antigen and immunostimulatory oligodeoxynucleotides induces specific immunity and protection against Leishmania donovani infection.
Tewary P; Pandya J; Mehta J; Sukumaran B; Madhubala R
FEMS Immunol Med Microbiol; 2004 Oct; 42(2):241-8. PubMed ID: 15364110
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
